Aridis Pharmaceuticals announces results from clinical trial of AR-105
Category: #health  By Saipriya Iyer  Date: 2019-09-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aridis Pharmaceuticals announces results from clinical trial of AR-105

Aridis Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company focused on developing innovative anti-infective therapies for the treatment of severe bacterial infections, recently announced results from clinical trial of a fully human IgG1 monoclonal antibody, AR-105 for the treatment of VAP (ventilator-associated pneumonia) caused by gram-negative P. aeruginosa (Pseudomonas aeruginosa).

As per sources close to the matter, primary endpoint of demonstrating superiority in clinical cure rates after completion of 21 days was not met in the recent study. Moreover, there was a statistically significant imbalance in SAE (serious adverse events) rates as well as in all-cause mortality between treatment groups that favored placebo.

Nevertheless, no mortality or SEA was deemed to be drug related by the study's Data Monitoring Committee or the study investigators.

Vu Truong, Ph.D., CEO of Aridis Pharmaceuticals was reportedly quoted saying that the company will remain enthusiastic and will re-focus on the balance of its robust pipeline including AR-501 and AR-301, which are still under clinical development phase.

He claims that AR-301, which targets gram-positive S. aureus alpha-toxin, is the company’s leading anti-body and is in global Phase 3 clinical development for the treatment of ventilator-associated pneumonia. He added that this trial is progressing on track and the company is looking forward to reporting interim data in the first half of 2020 along with subsequent top-line data by the end of 2020.

For the record, the development of AR-105, a mAb targeting cell surface carbohydrate on Pseudomonas aeruginosa, was based on animal models of acute pneumonia, keratitis and sepsis which supported its usage as both a prophylactic therapy and as a therapeutic. Focusing on therapeutic use of AR-105, a Phase 1 clinical trial of AR-105 was conducted which demonstrated it to be safe, well-tolerated and showed a plasma half-life of around 21 days.

In addition to AR-105, the company is also on track with its AR-501 program, an inhaled gallium citrate formulation which is being developed as a non-antibiotic anti-infective to medicate lung infections in patients with cystic fibrosis.

Source Credit: https://investors.aridispharma.com/2019-09-03-Aridis-Pharmaceuticals-Reports-Phase-2-Clinical-Trial-Results-of-AR-105-for-the-Treatment-of-Ventilator-Associated-Pneumonia-Caused-by-Pseudomonas-Aeruginosa



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...

Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
By Saipriya Iyer

Reliance Industries Ltd., an Indian conglomerate, has reportedly raised Rs.7,500 crore (Dollar 1.02 billion) by selling a stake in its retail unit to Silver Lake Partners, a private equity firm.

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
By Saipriya Iyer

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec G...